CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Biotron Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Biotron Ltd
Suite 3.3, 56 Delhi Road
Phone: +61 298050488p:+61 298050488 NORTH RYDE, NSW  2113  Australia Ticker: BITBIT
Business Summary
Biotron Limited is a clinical-stage biotechnology company. The Company is engaged in the research, development, and commercialization of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1 and COVID-19, and additional preclinical programs including Hepatitis B Virus (HBV). In addition, the Company has several early-stage programs designing drugs that target a class of virus protein known as viroporins, which have a key role in the virus life cycle of a range of viruses, such as Coronavirus, Dengue, Ebola, Middle East Respiratory virus, Influenza and Zika viruses. Its proprietary primary bacterial cell-based screening platform enables rapid screening of target viroporin proteins. Its lead compound, BIT225, is in Phase II development for the treatment of HIV-1. The Company also has a portfolio of preclinical antiviral programs.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20246/30/2024Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Non-Executive Chairman of the Board Michael J.Hoy 3/16/2000 2/7/2000
Managing Director, Executive Director MichelleMiller 1/1/2021 6/21/2002
Company Secretary MarceloMora 5/2/2025 5/2/2025
Independent Non-Executive Director Robert B.Thomas 78 3/7/2012 3/7/2012

General Information
Number of Employees: 4 (As of 6/30/2014)
Outstanding Shares: 1,804,765,532 (As of 3/5/2025)
Shareholders: 6,085
Stock Exchange: ASX
Fax Number: +61 298050688


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 11, 2025